Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcersExpanded strategic research collaborations with industry ...

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase ...

In one advertisement, Fife flagged in 2023, a skin substitute representative whose company name has been redacted boasts of a ...

Varicose veins are a common vascular condition that can cause discomfort, swelling, and aesthetic concerns. While visible ...

Despite staffing cuts at CMS, Organogenesis expects to manage through the challenges. Click here to read why I rate ORGO ...

UK biotechnology company SolasCure has commenced the randomised, controlled CLEANVLU2 Phase II trial of Aurase Wound Gel for chronic wound treatment, with the first subject enrolled. The patented ...

BioStem's Q4-2024 revenue expected to rise 794% YoY, with full-year net revenue increasing 1,702%. Read why I'm bullish on ...

SANUWAVE Health, Inc.’s SNWV share price has surged by 10.43%, which has investors questioning if this is right time to sell.

SolasCure, a Cambridge biotech developing a novel treatment to transform chronic wound healing, has initiated a new Phase II ...

Medical honey proves effective against antibiotic-resistant bacteria, transforming wound care and offering hope in the fight ...

The Mexico adhesive dressings market, valued at USD 225.54 million in 2024, is poised for significant growth, projected to reach USD 378.46 million by 2033 at a CAGR of 5.92% during the forecast ...